Miro Sciences clears TGA audit, aims to launch Crohn's trial by 2026
Miro Sciences has cleared a TGA audit of its manufacturing partner Q-Gen Cell Therapeutics ahead of a phase two clinical trial for its StemSmart therapy targeting refractory Crohn's disease. The inspection confirms compliance with strict GMP standards, enabling wider production. Miro aims to launch the trial by the end of 2026, potentially benefiting millions affected by the condition.
Take it further — get the full app and never miss a moment of what's happening in Australia.
This publisher's site can't be shown here due to their security settings.
Open full article →No source link available for this article.
Published 12 Nov 2026, 01:24 UTC · Updated 12 Nov 2026, 01:30 UTC
Summary by OZbrief Editorial. Original report: SMH. Editorial policy · Corrections
Trending
- Melbourne Uni cuts 179 staff as it bleeds cash for fifth year
- Melbourne art teacher Alice Krause apologizes after racist car park outburst
- Six Victoria fire stations robbed, CFA reviews security amid bushfire risks
- Finnish ambassador says interest in embassy no red herring after viral posts
- Dave Grohl pays tribute to Beaconsfield miner Todd Russell amid energetic Sydney
- Hussey makes call on Australia's best batting line up